Pillar Post
Pillar Biosciences Closes $29.7 Million in Series C Financing
Financing to Advance IVD and RUO Product Development and to Expand Global Commercialization Natick, MA, May 5, 2020—Pillar Biosciences, an NGS clinical cancer diagnostics company, …
Finding flexibility in a resource limited world: Online presentation
Time and resource optimization are top-of-mind for many clinical labs working with NGS. As a resource for clinical researchers and labs, we revisit this presentation …
The complexity of the NGS process, compounded by sample processing, results in unique challenges for clinical oncology laboratories
Increasingly, clinical samples of all types are being analyzed with the goal of matching patients to target therapies. In the summer of 2017, Thermo Fisher received …
5 reasons to go custom with your next sequencing panel
Off-the-shelf next-generation sequencing (NGS) panels save on sequencing costs by targeting specific genes, and the smaller resulting datasets are easier to analyze. The catch is, …
Garbage in, greatness out: making the most of FFPE samples
The cancer research community relies on formalin-fixed samples, but the quality of these samples degrades over time. Sequencing data from partially degraded samples is plagued …
Meet SLIMamp: Columbia University’s new tumor sequencing workhorse
Next generation sequencing (NGS) is a powerful diagnostic tool for identifying tumor variants. Tumor sequencing workflows often rely on off-the-shelf panels, which allow for multiplexed …
Workshop: Single-vial amplification-based NGS to interrogate variants in tumors with limited diagnostic material
Helen Fernandes, PhD, Co-director of Genomic Oncology at Columbia University, presented a talk on October 31, 2018 during the Corporate Workshop Day at the 2018 …
Dive straight into the feedback!Login below and you can start commenting using your own user instantly